Human Microbiome Market Size - By Site (Digestive Tract, Lung), Application (Therapeutics, Diagnostics), Disease (Infectious Diseases, Gastrointestinal Diseases), Product (Drugs, Diagnostic Tests, Probiotics) & Global Forecast 2023-2032

Description

List of Tables

Global Human Microbiome Market share will grow at 25.4% CAGR between 2023 and 2032, driven by the increasing funding initiatives and government programs worldwide prioritizing research in this field. Financial support for microbiome research accelerates scientific advancements, leading to the development of innovative therapies and diagnostic tools.

In July 2022, the Dumont-UCLA Transplant Center secured a combined $11.5 million in federal government grants to support research endeavors with the goal of extending the viability of donated organs and enhancing the overall health and longevity of transplant recipients. These grants, one provided by the National Institutes of Health and the other by the Department of Defense, are dedicated to advancing the outcomes of liver transplantation and hand and face transplantation. These investments attract pharmaceutical and biotechnology companies, fostering collaborations and expanding the market. The emphasis on understanding the role of the microbiome in health and disease positions the human microbiome industry for significant growth in the coming years.

The overall human microbiome market is segregated based on site, application, disease, product, and region.

The diagnostics segment could expand at a decent growth rate through 2032. The demand for human microbiome diagnostics is propelled by the growing awareness of the significant role the microbiome plays in health and disease. Researchers and healthcare professionals are increasingly recognizing that the composition of an individual's microbiome can provide valuable insights into various health conditions, including gastrointestinal disorders, autoimmune diseases, and even mental health issues. As a result, there's a rising interest in microbiome-based diagnostics, creating a demand for advanced testing and analysis methods.

The probiotics segment could capture a modest human microbiome industry share by 2032. Human microbiome probiotics are in high demand due to their potential to support gut health and overall well-being. These probiotics contain beneficial microorganisms that can help maintain a balanced gut microbiome, which is increasingly linked to various aspects of health, from digestion to immune function. Consumers seeking natural ways to improve their health are turning to microbiome probiotics, creating a strong market demand for these products.

Asia Pacific human microbiome industry is expanding due to several factors. A growing awareness of the pivotal role the microbiome plays in health is driving demand for microbiome-based products and services. Besides, the rise in chronic health conditions has spurred interest in microbiome research and therapies. Moreover, the region's increasing healthcare infrastructure and research investments further facilitate the growth of the human microbiome industry in the Asia Pacific.

Product Code: 6538

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Public sources

Chapter 2 Executive Summary

2.1 Global human microbiome industry 360 degree synopsis, 2018 - 2032
- 2.1.1 Business trends
- 2.1.2 Regional trends
- 2.1.3 Site trends
- 2.1.4 Application trends
- 2.1.5 Disease trends
- 2.1.6 Product trends

Chapter 3 Human Microbiome Industry Insights

3.1 Industry landscape
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing burden of lifestyle-related diseases and the growing geriatric population
  - 3.2.1.2 Increasing funding initiatives and government program
  - 3.2.1.3 Increasing demand precision medicine
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Long regulatory pathways and high development costs
  - 3.2.2.2 Ethical and safety concern
3.3 Growth potential analysis
- 3.3.1 By site
- 3.3.2 By application
- 3.3.3 By disease
- 3.3.4 By product
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
- 3.5.1 U.S.
- 3.5.2 Europe
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Company positioning matrix
4.5 Strategy dashboard, 2022

Chapter 5 Human Microbiome Market, By Site, 2018 - 2032 (USD Million)

5.1 Key trends, by site
5.2 Digestive tract
5.3 Lung
5.4 Reproductive cavity
5.5 Skin
5.6 Other sites

Chapter 6 Human Microbiome Market, By Application, 2018 - 2032 (USD Million)

6.1 Key trends, by application
6.2 Therapeutics
6.3 Diagnostics

Chapter 7 Human Microbiome Market, By Disease, 2018 - 2032 (USD Million)

7.1 Key trends, by disease
7.2 Infectious diseases
7.3 Gastrointestinal diseases
7.4 Endocrine & metabolic diseases
7.5 Cancer
7.6 Cetral nervous system disorder
7.7 Other diseases

Chapter 8 Human Microbiome Market, By Product, 2018 - 2032 (USD Million)

8.1 Key trends, by product
8.2 Drugs
8.3 Probiotics
8.4 Prebiotics
8.5 Diagnostic tests
8.6 Other products

Chapter 9 Human Microbiome Market, By Region, 2018 - 2032 (USD Million)

9.1 Key trends, by region
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Rest of Latin America
9.6 MEA
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 Rest of MEA

Chapter 10 Company Profiles

10.1 Seres Therapeutics
10.2 Enterome
10.3 Second Genome Inc.
10.4 DuPont
10.5 Synthetic Biologics, Inc.
10.6 Synlogic
10.7 Vedanta Biosciences, Inc.
10.8 Metabiomics Corporation
10.9 MICROBIOME THERAPEUTICS LLC
10.10 4D pharma plc